title: Altered expression of Smad proteins in T or NK-cell lymphomas.
abstract: OBJECTIVE
  Smad proteins mediate cellular signaling through the transforming growth factor-beta family (TGF-betas). Smads 2 and 3 transmit signals from TGF-beta, and Smad4 is a common mediator, as well. However, little is known concerning the expression patterns of Smads in lymphoid tissue.
  
  
  METHODS
  Immunohistochemistry for Smad3 and Smad4 was performed on paraffin-embedded tissue sections collected from 26 T- or NK-cell lymphomas.
  
  
  RESULTS
  Nearly all cells in germinal centers were positive for Smad3, and more than 50% of paracortical cells were positive for Smad3 in reactive lymphoid tissue. When Smad4 immunostaining was conducted, nearly all the cells in the germinal centers showed diffuse cytoplasmic staining, and most of them exhibited nuclear positivity, as well. In addition, more than 50% of the cells in the paracortex were positive for Smad4. Furthermore, the Smad3 staining pattern was preserved in all malignant lymphomas, but four of these cases (15%) exhibited decreased expression of Smad4. All lymphoblastic lymphomas showed strong positivity in most of tumor cells, but one unspecified peripheral lymphoma, two nasal NK/T cell lymphomas, and one anaplastic large cell lymphoma were negative for Smad4.
  
  
  CONCLUSIONS
  These results suggest that TGF-beta-specific Smads may be actively involved in signal transduction in lymphoid organs and that Smad-mediated TGF-beta signaling pathways are operative in malignant lymphoma. In addition, loss of Smad4 expression might be associated with development of some T-cell lymphomas.
authors.affiliation: Department of Pathology, Dankook University College of Medicine, Cheonan, Korea. jaihyang@yahoo.co.kr
authors.forename: Jai Hyang
authors.initials: JH
authors.lastname: Go
references.citation: Exp Cell Res. 2000 Nov 25;261(1):250-9
references.pmid: 11082295
references.citation: Int Immunol. 2003 Dec;15(12):1401-14
references.pmid: 14645149
references.citation: Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6002-6
references.pmid: 8016105
references.citation: Blood. 1999 Oct 15;94(8):2854-61
references.pmid: 10515889
references.citation: Hum Pathol. 1993 Mar;24(3):249-55
references.pmid: 7681031
references.citation: Leukemia. 2003 Sep;17(9):1731-7
references.pmid: 12970772
references.citation: Nat Rev Immunol. 2002 Jan;2(1):46-53
references.pmid: 11905837
references.citation: N Engl J Med. 2004 Aug 5;351(6):552-9
references.pmid: 15295048
references.citation: Int J Hematol. 1997 Feb;65(2):97-104
references.pmid: 9071813
references.citation: Pathol Res Pract. 2002;198(5):333-7
references.pmid: 12092769
references.citation: Cell. 1998 Sep 18;94(6):703-14
references.pmid: 9753318
references.citation: Dev Dyn. 2001 Feb;220(2):141-54
references.pmid: 11169847
references.citation: EMBO J. 1999 Mar 1;18(5):1280-91
references.pmid: 10064594
references.citation: Cell. 1998 Mar 6;92(5):645-56
references.pmid: 9506519
references.citation: Nat Rev Immunol. 2007 Jun;7(6):443-53
references.pmid: 17525753
references.citation: Cell Growth Differ. 2000 Jan;11(1):1-10
references.pmid: 10672898
references.citation: J Biol Chem. 2000 Jan 21;275(3):2115-22
references.pmid: 10636916
references.citation: Am J Pathol. 1990 Jun;136(6):1209-14
references.pmid: 2356855
references.citation: J Hematother Stem Cell Res. 2001 Feb;10(1):67-74
references.pmid: 11276360
references.citation: Mol Cell Biol. 1996 Jul;16(7):3480-9
references.pmid: 8668164
references.citation: J Biol Chem. 2000 Dec 8;275(49):38363-70
references.pmid: 10995749